SCHEMBL19985667

SCHEMBL19985667

Oc1cccc(Nc2cccc3c2CCCC3)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.47
BAD Q92934 1/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
EGFR P00533 3/20 0.45
RAPGEF4 Q8WZA2 1/20 0.45
SHMT2 P34897 1/20 0.45
ALDH1A1 P00352 2/20 0.44
BRAF P15056 2/20 0.44
HDAC6 Q9UBN7 1/20 0.44
GRIN2D O15399 1/20 0.43
GRIN3B O60391 1/20 0.43
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
GRIN2C Q14957 1/20 0.43
GRIN3A Q8TCU5 1/20 0.43
SIGMAR1 Q99720 1/20 0.43
MEN1 O00255 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428962 0.82 MEN1 (0.50) BCL2L1BADSHMT2ALDH1A1MEN1
SCHEMBL30505569 0.82 MEN1 (0.50) BCL2L1BADSHMT2ALDH1A1MEN1
SCHEMBL4934258 0.81 SHMT2 (0.51) EGFRSHMT2ALDH1A1MEN1LMNA
SCHEMBL21625850 0.81 RAPGEF4 (0.47) EGFRRAPGEF4SHMT2ALDH1A1GRIN2D
SCHEMBL19987387 0.81 BCL2L1 (0.47) BCL2L1BADEGFRALDH1A1GRIN2D
SCHEMBL19993717 0.80 BCL2L1 (0.46) BCL2L1BADTSHREGFRALDH1A1
SCHEMBL12101466 0.79 MEN1 (0.56) BCL2L1BADEGFRSHMT2ALDH1A1
SCHEMBL12377131 0.78 NISCH (0.51) CYP3A4TSHRSHMT2ALDH1A1SIGMAR1
SCHEMBL4785268 0.78 FADS1 (0.50) TSHREGFRSHMT2ALDH1A1LMNA
SCHEMBL19985759 0.76 CCR4 (0.47) BCL2L1BADALDH1A1GRIN2DGRIN3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3516019-B1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS CORP (US) 2023-06-14 EP disclosed
EP-3516020-B1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS CORP (US) 2022-05-25 EP disclosed
US-10723969-B2 Lubricant compositions stabilized by mixtures of diarylamine and hydroxydiarylamine antioxidants LANXESS SOLUTIONS US INC. (US) 2020-07-28 US disclosed
US-10563145-B2 Alkylated 3-hydroxydiphenylamine antioxidants LANXESS SOLUTIONS US INC. (US) 2020-02-18 US disclosed
WO-2018057366-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. (US) 2018-03-29 WO disclosed
WO-2018057364-A1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. (US) 2018-03-29 WO disclosed
US-20180079985-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed
US-20180079987-A1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed
US-20180079985-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed
US-20180079987-A1 LUBRICANT COMPOSITIONS STABILIZED BY MIXTURES OF DIARYLAMINE AND HYDROXYDIARYLAMINE ANTIOXIDANTS LANXESS SOLUTIONS US INC. 2018-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180079985-A1 ALKYLATED 3-HYDROXYDIPHENYLAMINE ANTIOXIDANTS GPX4, GSTO1, LPO BCL2L1 1233/4885BAD 1771/4885CYP3A4 478/4885
US-10563145-B2 Alkylated 3-hydroxydiphenylamine antioxidants GPX4, GSTO1, LPO BCL2L1 1233/4885BAD 1771/4885CYP3A4 478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.